BTIG Rates Monopar Therapeutics (MNPR) buy, $117 Price Target

BTIG maintains its positive outlook on MNPR, setting a $117 price target, a 23.73% upside from the current price.

By EarningsIQ Research Desk · Published Jun 30, 2026, 7:01 AM EDT · Updated Jul 1, 2026, 2:01 AM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

BTIG rated Monopar Therapeutics Inc. ($MNPR) "buy" with a $117 price target on June 30, 2026.

Since the rating, $MNPR is up 2.8% after 1 week, up 23.8% after 1 month and down 25.2% to date (from the $92.59 close on Jun 30, 2026).

MNPR Monopar Therapeutics Inc.

$69.27 +4.94% year to date

Daily close · Oct 16, 2026

Key Points

BTIG reiterated its Buy rating on MNPR with a $117 price target on June 30, 2026.
BTIG's $117 price target implies 23.73% upside from Monopar Therapeutics Inc.'s ($MNPR) current $94.56 share price.
Shares of MNPR traded near $94.56 on Tuesday, with insider buying reported earlier this year.
Other analysts, like HC Wainwright & Co., also reiterated Buy ratings with targets of $105.

Get $MNPR trade alerts by text

We text you when insiders, Congress or big funds trade $MNPR. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Monopar Therapeutics Inc. alert may contain errors. Disclosures

BTIG reiterated its Buy rating for MNPR on June 30, 2026, setting a price target of $117. Analyst Jeet Mukherjee maintains a positive outlook on the stock, which traded near $94.56 on Tuesday.

Analyst rating track record

BTIG vs. the S&P 500

YTD return -22.38% hypothetical

All-time return +27.09% S&P 500 +39.96%

vs. S&P 500 -12.87% behind the index

Hypothetical returns from BTIG's disclosed trades, not real profit or advice. How we model this.

Other Institutional Activity in MNPR

Janus Henderson Group PLC held steady with 1,317,410 shares valued at about $72.1 million. RA Capital Management, L.P. also kept its position unchanged, holding 667,207 shares worth around $36.6 million. Meanwhile, Saturn V Capital Management LP increased its stake by 19,925 shares to a total of 345,626 shares, valued at approximately $18.9 million, marking a 6.1% increase. Deerfield Management Company, L.P. significantly boosted its holdings by 153,187 shares, a hefty 89.8% increase, bringing its total to 323,745 shares worth $17.7 million. In contrast, Adage Capital Partners GP, L.L.C. reduced its holdings by 330,272 shares, a 51.6% decrease, ending with 309,195 shares valued at $16.9 million.

Monopar Therapeutics Inc. Stock Down 2.0%

Shares of MNPR traded near $94.56 on Tuesday. The stock has seen varied institutional activity, with some funds increasing their stakes and others reducing them. This movement reflects differing views on MNPR's future potential.

12-month forecast

$MNPR price target

Monopar Therapeutics Inc. daily closes and this analyst's $117 target. Not advice.

Insider Buying and Selling at Monopar Therapeutics Inc.

Recent insider activity at MNPR includes several purchases. On March 2, 2026, Susan Rodriguez, the Chief Customer Service Officer, bought 48,728 shares. Earlier, on January 28, 2025, Chandler Robinson, the CEO, acquired 62,815 shares. Additionally, Patrice Rioux purchased 2,000 shares on January 1, 2026, and Andrew Cittadine, the COO, bought 4,326 shares on December 31, 2025.

Analysts Set New Price Targets

On June 30, 2026, BTIG maintained its Buy rating on MNPR with a $117 price target. A day prior, HC Wainwright & Co. reiterated its Buy rating with a target of $105. Earlier in the year, Chardan Capital also maintained a Buy rating with a $100 target on March 30, 2026. These consistent Buy ratings suggest analysts see potential upside for MNPR.

Bottom Line

BTIG's reiterated Buy rating and $117 target for MNPR highlight continued confidence in the stock's prospects. Investors often track these analyst updates as part of their decision-making process. It's important to remember that these ratings reflect past analyses and may not indicate current positions or future performance.